Table 1. Patient Characteristics Patient... | American Society of Hematology

Table 1.

Patient Characteristics

Patient No.	Age	Stage Dx	BM Status (%plasma cells)	Time From Diagnosis (mo)	Prior Therapy
1	62	IIIA	30-40	3	D/VAD
2	45	IIIA	<5	28	VAD/allogeneic BMT
3	50	IIA	<5	7	D
4	43	IIA	<5	18	D/C/EDAP/CD34⁺ PBSCT
5	66	IIIA	<5	5	D/VAD
6	49	IIIA	30	15	D/CD34⁺ PBSCT
7	52	IIIA	<5	11	MP/D
8	38	IIIA	<5	13	VAD/CD34⁺ PBSCT
9	60	IIIB	70	0	None
10	56	IIIA	<5	39	VAD/allogeneic BMT
11	63	IIIA	30	10	C
12	57	IIA	<5	10	VAD/CD34⁺ PBSCT
13	50	IIIB	>90	15	MP/VAD/CD34⁺ PBSCT
14	69	^*	<5	17	XRT/VAD/CD34⁺ PBSCT
15	58	IIIB	50-60	50	MP/VAD/C
16	62	IIIA	70-80	30	VAD/CD34⁺ PBSCT
17	60	IIIA	<5	24	VAD/CD34⁺ PBSCT
18	77	IIIA	80-90	0	None

Patient No.	Age	Stage Dx	BM Status (%plasma cells)	Time From Diagnosis (mo)	Prior Therapy
1	62	IIIA	30-40	3	D/VAD
2	45	IIIA	<5	28	VAD/allogeneic BMT
3	50	IIA	<5	7	D
4	43	IIA	<5	18	D/C/EDAP/CD34⁺ PBSCT
5	66	IIIA	<5	5	D/VAD
6	49	IIIA	30	15	D/CD34⁺ PBSCT
7	52	IIIA	<5	11	MP/D
8	38	IIIA	<5	13	VAD/CD34⁺ PBSCT
9	60	IIIB	70	0	None
10	56	IIIA	<5	39	VAD/allogeneic BMT
11	63	IIIA	30	10	C
12	57	IIA	<5	10	VAD/CD34⁺ PBSCT
13	50	IIIB	>90	15	MP/VAD/CD34⁺ PBSCT
14	69	^*	<5	17	XRT/VAD/CD34⁺ PBSCT
15	58	IIIB	50-60	50	MP/VAD/C
16	62	IIIA	70-80	30	VAD/CD34⁺ PBSCT
17	60	IIIA	<5	24	VAD/CD34⁺ PBSCT
18	77	IIIA	80-90	0	None

DCs were generated from a range of MM patients during different stages of disease with variable treatment histories. Treatment included D (Dexamethasone), VAD (Vincristine, Adriamycin, Dexamethasone), EDAP (Etoposide, Dexamethasone, Ara-C, and Cisplatinum), C (Cyclophosphamide), MP (Melphalan, Prednisolone), BMT (bone marrow transplant), PBSCT (peripheral blood stem cell transplant), and XRT (Radiotherapy).

Patient 14 had a plasmacytoma of the bone.

View Large